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CApecitabine plus Radium-223 (Xofigo™) in
breast cancer patients with BONe
metastases (CARBON): study protocol for a
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Rob Coleman1, Janet Brown1, Emma Rathbone2, Louise Flanagan3, Amber Reid3, Jessica Kendall3*, Sacha Howell4,
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Abstract
Background: A substantial proportion of breast cancer patients develop metastatic disease, with over 450,000
deaths globally per year. Bone is the most common first site of metastatic disease accounting for 40% of all
first recurrence and 70% of patients with advanced disease develop skeletal involvement.
Treatment of bone metastases currently focusses on symptom relief and prevention and treatment of skeletal
complications. However, there remains a need for further treatment options for patients with bone metastases.
Combining systemic therapy with a bone-targeted agent, such as radium-223, may provide an effective treatment with
minimal additional side effects.
Methods/design: CARBON is a UK-based, open-label, multi-centre study which comprises an initial safety phase to
establish the feasibility and safety of combining radium-223 given on a 6-weekly schedule in combination with orally
administered capecitabine followed by a randomised extension phase to further characterise the safety profile and
provide preliminary estimation of efficacy.
Discussion: The CARBON study is important as the results will be the first to assess radium-223 with chemotherapy in
advanced breast cancer. If the results find acceptable rates of toxicity with a decrease in bone turnover markers, further
work will be necessary in a phase II/III setting to assess the efficacy and clinical benefit.
Trial registration: ISRCTN, ISRCTN92755158, Registered on 17 February 2016.
Keywords: Radium-223, Capecitabine, Bone metastases, Bone turnover markers, Breast cancer
Background
Metastatic breast cancer
Despite significant advances and improvements in out-
comes following breast cancer, a significant proportion
of patients still develop metastatic disease with bone be-
ing the most common first site for distant metastasis.
Metastatic tumour development is thought to follow
complex interactions between the tumour cell and the
bone microenvironment allowing occupation of the
haematopoietic stem cell and other cellular niches in the
bone marrow by tumour cells. Tumour-derived factors
attract and stimulate osteoclasts, increasing bone turn-
over and releasing bone-activated growth factors and
cytokines [1]
The skeletal lesions seen in association with breast
cancer are most commonly osteolytic and associated
with significant morbidity due to the skeletal complica-
tions, termed skeletal-related events (SREs): severe bone
pain requiring radiation, pathological fracture, spinal
cord or nerve root compression, hypercalcaemia and the
requirement of surgery or radiation to bone. However,
there is usually an osteoblastic component that is
manifested by the visualisation of bone metastases on
radionuclide bone scans and elevation of osteoblastic
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bone markers such as bone-specific alkaline phosphat-
ase (B-ALP). Although sometimes identified on
imaging tests, most SREs are associated with symp-
toms when they are known as symptomatic skeletal
events (SSEs). The median survival time after the de-
velopment of bone metastases is approximately 2–3
years.
Bone turnover markers, biological indicators of either
bone resorption or bone formation, are associated with
clinically relevant endpoints. N-telopeptide of type-I col-
lagen (NTX) is derived from the breakdown of type-1
collagen during bone remodelling and reflects the rate of
bone resorption. Elevated levels of urinary NTX (uNTX)
are associated with significantly increased rate of SREs
and disease progression amongst a solid tumour popula-
tion, in addition to increased mortality. B-ALP is a
bone-formation marker which is similarly associated
with negative outcomes in patients with elevated levels
[2].
There are many treatment options available to pa-
tients with advanced breast cancer including surgery,
radiotherapy and systemic therapies. Current treat-
ment of bone metastases also focusses on symptom
relief and treatment and prevention of SREs. Anti-
resorptive agents, such as bisphosphonates or
denosumab, delay SREs and are subsequently now
widely established as standard therapy for such pa-
tients [3–6]. Additionally, bisphosphonates suppress
bone turnover markers, with their normalisation or
degree of suppression correlating with reduced SREs
and death rate [7]. However, there remains a need
for further treatment options for patients with bone
metastases to improve survival more than 2–3 years.
Combining systemic therapy with a bone-targeted
agent, such as radium-223, may provide an effective
treatment with minimal additional side effects.
Radium-223
Radium-223 dichloride (radium-223) is a novel alpha-
emitting pharmaceutical that has been developed for the
treatment of bone metastases. The product is based on
the alpha-emitting radionuclide radium-223. The intrin-
sic bone-targeting property of radium-223 compounds is
similar to that of other alkaline earth elements, like cal-
cium. The characteristics of alpha-emitting radionuclides
have benefits over beta-emitting radionuclides for bone
targeting. Firstly, radium-223 emits alpha-particles with
high linear-energy transfer and a radiation range limited
to less than 100 μm [8–11]. This generates a highly
localised and effective radiation zone with high probabil-
ity of inducing double-strand DNA breaks in the cancer
cells. LOn the other hand, beta-emitting radiopharma-
ceuticals, such as strontium, emit particles with lower
energy, mainly inducing single-strand breaks which
are more easily repaired. Additionally, beta-particles
typically have 30–80 times longer radiation range
compared to alpha-particles. An alpha-emitting radi-
ation source located in a target tissue, such as bone
metastases, will deliver higher energy radiation to a
more localised volume than beta emitters, thereby re-
ducing exposure of surrounding normal tissues and
leading to less toxicity, importantly less myelotoxicity.
Radium-223 received Food and Drug Administration
(FDA) approval in 2013 for the treatment of patients
with castration-resistant prostate cancer (CRPC) and
bone metastases [12].
Pre-clinical data
Pre-clinical data in an experimental skeletal metastasis
model in nude rats inoculated intravenously with human
breast cancer cells demonstrated a significant radium-
223 anti-tumour effect and showed significantly
symptom-free survival [13].
Clinical data
Since radium-223 began clinical development in 2001
there have been several phase I studies in patients
with bone metastases from prostate or breast cancer.
These showed that the drug is quickly eliminated
from blood, taken up by bone and excreted via the
small intestine [13]. The kidneys, bladder and urethra
are, therefore, exposed to minimal amounts of radi-
ation. No specific uptakes were seen in the heart,
liver, kidney, gallbladder, stomach or spleen. The
highest absorbed doses were measured in the bone
and red marrow.
Pain relief was observed in studies using both sin-
gle doses and multiple doses of radium-223, with
better pain relief being observed with the higher
doses [14, 15]. Decreases in B-ALP were observed at
all dose levels, similarly more pronounced at the
higher doses [14].
Multiple dosing at 6-weekly intervals was evaluated in
the BC1–04 study, a phase II study in patients with
symptomatic or non-symptomatic hormone-refractory
prostate cancer. One hundred and twenty-two patients
received three doses of 25, 50 or 80 kBq/kg. A significant
dose-response relationship was seen, with an increasing
proportion of prostate-specific antigen (PSA) responders
and B-ALP responders with increasing dose. The two
highest dose levels had a greater effect than the lowest
dose levels, with no significant difference between 50
and 80 kBq/kg [16].
Prostate cancer – single agent and combination with
chemotherapy
The majority of studies to date have been in prostate
cancer using radium-223 as a single agent. In a placebo-
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controlled, phase II study in hormone-refractory prostate
cancer patients with bone metastases, patients were
assigned 4 × 50-kBq/kg radium-223 injections (n = 33) or
saline injections (n = 31) given every 4 weeks [17]. The
median relative change in B-ALP was significantly
greater in the treatment arm compared with the control
arm (− 65.6% vs. 9.3%; P < 0.0001). Toxicity from
radium-223 is mild and tolerable. The most common
Adverse Events (AEs) were reversible myelosuppression,
diarrhoea, nausea and vomiting, with all reported as mild
or moderate in severity. A combined analysis of 300 pa-
tients treated with radium-223 showed that radium-223
is well tolerated with a low propensity for haemato-
logical toxicity [18].
The phase III registration study of radium-223
(ALSYMPCA) was performed in 921 patients with CRPC
and bone metastases and compared best supportive care
with radium 50 kBq/kg every 4 weeks for six cycles or
placebo. The primary endpoint was overall survival.
Patients who received radium-223 had a significant 3.6-
month improvement in median survival (hazard ratio
(HR) = 0.70; 95% confidence interval (CI), 0.58–0.83; P =
0.001) compared with patients who received placebo
[12]. These benefits were achieved without significant
toxicity and with additional benefits on the frequency of
SSEs, even in the presence of concomitant bisphospho-
nates [19].
Rationale for using radium-223 to treat metastatic breast
cancer
The mechanism of action and efficacy of radium-223
in prostate cancer suggests that the agent may be ef-
fective in other cancers that have a propensity to
metastasise to the bone. This was confirmed in an
open-label, phase IIa, non-randomised study of
radium-223 in breast cancer patients with bone-
dominant disease. This study evaluated any clinically
relevant effect on bone markers in breast cancer pa-
tients who had progressed on endocrine treatment
and were no longer considered suitable for further
endocrine therapy.
Radium-223 significantly reduced uNTX and B-ALP
from baseline to end of treatment. Radium-223 was safe
and well tolerated [16]. Therefore, it is important to
assess the toxicity and efficacy of radium-223 in a popu-
lation of patients that commonly requires chemotherapy.
Currently, larger randomised trials are evaluating the
addition of radium-223 to an aromatase inhibitor alone
or with everolimus (ClinicalTrials.gov Identifiers:
NCT02258451 and NCT02258464). The results are an-
ticipated in 2020. Combinations with chemotherapy
are also of interest for treatment later in the clinical
course. Capecitabine was selected due to its frequent
use as a single agent in breast cancer and relative
lack of myelotoxicity. The combination may, there-
fore, target both bone metastases and visceral
metastases.
There are ongoing studies combining radium-223 with
endocrine treatments (NCT02258464 and NCT02258451)
and a small safety study (n=15) has evaluated the combin-
ation of paclitaxel and radium-223 in a mixed population
of cancer patients [1], but thisThis will be the first study
to specifically assess radium with chemotherapy in ad-
vanced breast cancer.
Methods/design
Study aims and objectives
The purpose of this study is to determine the safety
profile and clinical relevance of the combination of
radium-223 and capecitabine in breast cancer patients
with bone metastases. The study protocol and this
manuscript have been written in accordance with Stand-
ard Protocol Items: Recommendations for Interventional
Trials (SPIRIT) guidelines.
Primary objectives
 To evaluate the safety and toxicity of the
combination of radium-223 and capecitabine
 To preliminarily estimate if multiple intravenous
(i.v.) injections of radium-223 plus capecitabine will
have any clinically relevant effect on uNTX in breast
cancer patients with bone metastases, with or
without other sites of disease
The sample size calculation is based solely on the
primary toxicity endpoint. Primary analysis of the
uNTX endpoint is focussed on estimation only, i.e. no
formal hypothesis testing will be carried out for the
purpose of decision making. No formal comparisons
will be made.
Secondary objectives
To evaluate the effect of radium-223 on other bone
turnover markers (N-terminal propeptide of procolla-
gen type-1 (P1NP), serum C-telopeptide (CTX), pyri-
dinoline cross-linked carboxyterminal telopeptide
(1CTP), B-ALP)
 To evaluate pain scores and quality of life
 To evaluate time to first SSE – defined as any of: use
of external-beam radiotherapy to relieve skeletal
symptoms; new symptomatic pathological vertebral
or non-vertebral bone fracture; spinal cord compres-
sion; tumour-related orthopaedic surgical
intervention
 To evaluate time to progression of bone disease and
time to progression of extraskeletal disease
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Study design
The trial is designed as a randomised, controlled, open-
label, multi-centre, phase IB/IIA study. It comprises an
initial safety phase to establish the feasibility and safety
of combining radium-223 at the recommended dose of
55 kBq/kg given on a 6-weekly schedule to enable
combination with orally administered capecitabine ad-
ministered with the standard of care schedule (2 weeks
of capecitabine followed by 1 week off treatment).
Recruitment to the initial safety phase utilises a 3 + 3 de-
sign. If the treatment in the initial safety phase proves to
be feasible and safe, the randomised extension phase will
open to recruitment. The extension phase of the study
aims to characterise the safety profile and provide pre-
liminary estimation of efficacy.
The participant pathway can be seen schematically in
Fig. 1 and a populated Standard Protocol Items: Recom-
mendations Figure is also provided in Fig. 2.
Study population
Patients are eligible if they have histological evidence of
primary breast cancer with imaging evidence of bone
metastases (with or without soft tissue, lymph node or
visceral metastases; brain metastases allowed if stable
and untreated for ≥ 8 weeks) and systemic chemotherapy
with capecitabine is felt to be appropriate by the treating
physician. They must have received no more than two
lines of chemotherapy in the metastatic setting and prior
cytotoxic therapy must have been completed 28 days or
more prior to initiation of study treatment. They must
have an Eastern Co-operative Oncology Group (ECOG)
performance status 0–2 and a life expectancy of 6 or
more months. Patients are required to have appropriate
haematological and biochemical parameters, to be aged
18 years or over and be able and willing to consent and
comply with study treatment, visits and required
investigations.
Patients are excluded from the study if they are preg-
nant or breast feeding; received an investigational drug
within 4 weeks prior to the first study treatment;
received external-beam radiotherapy within 4 weeks
prior to the first study treatment; they have the presence
of imminent or established spinal cord compression
based on clinical findings and/or magnetic resonance
imaging (MRI); presence of other currently active (diag-
nosis within the last 5 years) malignancy (except treated
non-melanoma skin cancer (basal or squamous), carcin-
oma in situ of the cervix and superficial bladder can-
cers). Patients are also excluded if they have had severe
and unexpected reactions to fluoropyrimidine therapy or
have been diagnosed with dihydropyrimidine dehydro-
genase deficiency; received a blood transfusion or
erythropoietin within 4 weeks of study treatment; are
hypersensitive to capecitabine or any of its excipients;
have received treatment with sorivudine or its chem-
ically related analogues, such as brivudine; and are
receiving treatment with phenytoin or warfarin. Patients
with any other serious illness or medical condition will
be excluded, such as, but not limited to: any uncon-
trolled infection, clinical heart failure (NYHA Heart
Failure Class III or IV), active Crohn’s disease or
ulcerative colitis, bone marrow myelodysplasia, uncon-
trolled coronary artery disease, active peptic ulcers,
malabsorption.
Sample size
Approximately 48 participants will be recruited across
both phases of the trial.
Initial safety phase
A minimum of six and a maximum of 12 evaluable par-
ticipants will be recruited into the initial safety phase.
This is based on the number of participants experiencing
Dose Limiting Toxicities (DLTs), using a modified 3 + 3
approach (see Fig. 3).
Extension phase
An additional 36 participants will be recruited to the ex-
tension phase, and will be randomised on a 1:2 ratio to
receive either:
 Orally administered capecitabine alone 1000 mg/m2
twice a day (bd) or, capecitabine 850 or 1000 mg/m2
bd (as determined in the initial safety phase) plus
radium-223 55 kBq/kg by i.v. injection on day 1 of
cycle (2, 4, 6, 8, 10 and 12) of capecitabine for a total
of six injections.
The sample size for the extension phase is based
upon the primary toxicity endpoint of grade-III/IV
toxicity. With 24 participants in the capecitabine plus
radium-223 arm, this provides approximately 80%
power to exclude a grade-III/IV diarrhoea rate of 25%
from the upper limit of a one-sided 85% CI, assuming
a rate of approximately 10% with capecitabine alone.
If no more than 3/24 participants experience grade-
III/IV diarrhoea the upper limit of the one-sided 85%
CI will exclude 25%.
The control arm is included to provide concurrent
standard of care data for interpretation only. No formal
comparisons between arms will be made.
Recruitment
Participants are recruited from NHS hospitals through-
out the UK which are approved to participate in this
study having obtained requisite ethical and management
approval. There are four centres open to recruitment;
Weston Park Hospital in Sheffield, St James’s Hospital in
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Leeds, The Christie Hospital in Manchester and the
Clatterbridge Cancer Centre in Liverpool. These centres
have been selected based on their proven track record in
delivering early phase studies and experience with
radium-223. Further centres may be considered if the re-
cruitment target is not being met. The estimated accrual
for this study is two to three participants a month. Thus,
participant accrual is expected to be completed within
18months.
Study treatment
A maximum of 12 cycles of combination therapy is
given unless disease progression or unacceptable tox-
icity are encountered. A cycle is 21 days in accord-
ance with the standard administration of
capecitabine.
A maximum of two doses of capecitabine are being
investigated in this study; 850 mg/m2 bd and 1000
mg/m2 bd. The starting dose is 1000 mg/m2 bd which
Fig. 1 Participant pathway
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is in accordance with the standard administration of
capecitabine. Capecitabine is delivered on days 4–17
for up to 12 cycles to provide a 3–4-day window be-
fore and after radium-223 to minimise any risk of
potentiating normal tissue radiation sensitivity. After
cycle 12, patients may continue with capecitabine off
study as per standard of care, if they are continuing
to receive clinical benefit.
Radium-223 is administered at 55 kBq/kg. This dose
has been selected based on clinical data from previous
studies in prostate cancer and breast cancer which have
demonstrated efficacy and tolerability [14, 16–18].
Radium-223 is administered as a slow i.v. injection on
day 1 of alternating cycles, starting at cycle 2 to provide
one cycle of safety information in each participant with
capecitabine alone.
Initial safety phase
The safety data for the first cohort is reviewed by
the Safety Review Committee and the capecitabine
dose will either be expanded to a further three
participants or de-escalated to 850 mg/m2 bd de-
pending on the frequency and severity of toxicity
experienced.
Toxicity data for each subsequent cohort is
reviewed prior to dose expansion after three
Eligibility 
screening 
Registration / 
Randomisation 
Baseline 
Cycles 1, 3, 
5, 7, 9, 11 
Cycles 2, 6, 
10, 12  
Cycles 
4 and 8 
End of 
study 
Follow up 
(every 12 
weeks until 
progression)1 
ENROLMENT
Eligibility 
screening X
Informed consent X 
Medical history X 
Registration / 
Randomisation
X 
INTERVENTIONS
Capecitabine 
prescribed
X 
X X   
Radium-223 
administered
X X   
ASSESSMENTS
Physical, vital 
signs
 X 
X 
X X X X 
Weight
 X 
X 
X X   
ECOG PS
 X 
X 
X X X X 
ECG
 X 
Pregnancy Test
X X 2 X2 
Haematology3 
 X 
X 
X X X  
Biochemistry
 X 
X 
X X X  
 Serum & urine for 
bone markers
 X4 X X X  
Bone scintigraphy
  X   X 
CT / MRI
  X X  X 
Concomitant 
medications
 X 
X 
X X X  
Pain assessment 
(BPI)
 X X X X X 
QoL
  X X X X 
Survival status & 
disease 
progression 
   X 
AEs & SAEs
 Monitored from consent until 30 days after last administration of trial treatment. 
AEs of interest, 
SARs, SUSARs
Monitored from consent until the end of the trial (if judged to be related to radium-
223 and/or capecitabine)
1. Until 12 months after final patient enrolled 
2. Prior to radium-223 administration for pre/peri menopausal patients 
3. Additional haematology on cycle 1 day 8, cycle 1 day 15, cycle 2 day 8 and cycle 2 day 15 (+/- 2 days)  
4. Two serum and urine samples should be taken within 7 days prior to initial capecitabine administration. 
Fig. 2 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) Figure. Schedule of enrolment, interventions and assessments
for participants who are suitable for enrolment to the trial
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participants have been recruited and observed for
DLTs, according to Fig. 3.
DLTs are assessed during the second cycle of capecita-
bine treatment up to the administration of cycle 3 day 1
and will be defined as the following events:
 Gastrointestinal toxicity of ≥ grade III lasting > 48 h
despite adequate supportive care measures
 Haematological toxicity ≥ grade IV lasting > 7 days
despite adequate supportive care measures which
should exclude the use of bone marrow growth factors
Gastrointestinal toxicity ≥ grade III or haematological tox-
icity≥ grade IV experienced by participants during the first
cycle, i.e. up to the administration of cycle 2 day 1 are not
classed as DLTs as they are related to the capecitabine only.
The number of participants recruited to the initial
safety phase, and the dose carried forward to the rando-
mised extension phase is determined by the number of
DLTs in line with the DLT schema.
Evaluability
Participants can miss no more than 50% of doses in the
first two treatment cycles in order to be evaluable for
DLT in the initial safety phase. Participants missing
more than 50% of doses for reasons other than toxicity
without experiencing a DLT will be replaced.
Assessments
Participants are assessed clinically at baseline, on day 1
of each cycle, with additional haematology assessments
during cycles 1 and 2 (days 8 and 15, respectively), at
Fig. 3 Dose Limiting Toxicity (DLT) schema
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the end of study visit, and then at the 12-weekly follow-
up visits.
Planar bone scintigraphy/SPECT ± computerised
tomography (CT) is performed at baseline and at the
end of study visit, and when clinically indicated.
Chest/abdominal/pelvic CT or MRI is performed at
baseline, weeks 12 and 24 after the initiation of treat-
ment, at the of study visit and when clinically
indicated.
Serum and second voided urine samples are collected
to analyse changes in bone turnover markers at baseline,
day 1 of alternating cycles starting at cycle 2, and at the
end of the study visit.
Quality of life is assessed using EORTC QLQ-C30 and
QLQ-Bone Metastases Module (QLQ-BM22) which will
be completed by the participant prior to the first admin-
istration of trial treatment, day 1 of alternating cycles
starting at cycle 2, and at the end of study visit.
Response is evaluated using RECIST v1.1 with com-
parisons to baseline evaluation.
Data collection and management
All protocol-required information is completed at sites
onto paper Case Report Forms by research staff, with
the exception of quality-of-life information which will be
completed directly by participants. Overall trial and data
management is provided by the Leeds Clinical Trials Re-
search Unit (CTRU), including monitoring of data for
quality and completeness.
The independent Safety Review Committee (SRC)
meets regularly to review the safety and ethics of the
study by regularly reviewing the safety data during the
dose escalation and expansion phases.
Statistical analysis
Statistical analysis is the responsibility of the CARBON
CTRU trial statistician. A full statistical analysis plan will
be written before any formal analyses are undertaken.
During the initial safety phase, after every cohort of
three participants, the CTRU trial statistician produces a
summary of DLTs and AEs at each dose level, detailed
safety listings and treatment compliance data for all par-
ticipants in the study. The final analysis of primary end-
points and all secondary endpoints will take place when
all participants have been followed up for at least 12
months.
The analysis population for the initial safety phase in-
cludes any participant who has received at least one
complete cycle of capecitabine and radium-223. For the
extension phase intention-to treat (ITT) population, per-
protocol and safety analysis populations will be used.
Statistical analysis is summarised by treatment arm.
Primary endpoint analysis
Dose Limiting Toxicities (initial safety phase)
The number of participants experiencing DLTs within
the first cycle of radium-223 treatment will be presented,
with descriptive summaries of the specific DLTs
observed.
Frequency of CTC grade-III/IV toxicities with a focus on
diarrhoea as the primary toxicity (extension phase)
The number of participants experiencing any grade-III/
IV toxicity will be presented by arm, across all cycles as
well as by each cycle. Toxicities should be graded using
the National Cancer Institute Common Terminology
Criteria for Adverse Events version 4.03 (NCI CTCAE).
Decrease in uNTX from baseline to end of cycle 5
(approximately 15 weeks post trial entry) (extension phase)
The proportion of participants categorised as responders
(≥ 30% reduction in uNTX from baseline) at the end of
cycle 5 will be presented by arm.
Secondary endpoint analysis
Safety endpoints
 The number of Serious Adverse Events (SAEs),
Serious Adverse Reactions (SARs) and Serious
Unexpected Adverse Reactions (SUSARs) will be
summarised descriptively by arm, causality,
seriousness and body system
 The worst AE for each participant will be
summarised by arm, overall and by treatment cycle.
The proportion of participants experiencing each
toxicity will be summarised by maximum NCI
CTCAE (V4.03) grade by arm
 Dose delays and reductions will be summarised by
arm overall and by treatment cycle
Efficacy endpoints
 Descriptive and graphical summaries of the changes
in serum bone turnover markers will be presented
by arm. Multi-level repeated-measures modelling
will also be used to estimate differences between the
two treatment arms over time
 Time to occurrence of first symptomatic skeletal
event (SSE) will be calculated using the Kaplan-
Meier method. Median time to first SSE will be pre-
sented with corresponding 95% CIs for each arm
 Time to progression of bone disease will be
calculated using the Kaplan-Meier method. Median
time to progression of bone disease will be pre-
sented, with corresponding 95% CIs for each arm
 Time to progression of extraskeletal disease will be
calculated using the Kaplan-Meier method. Median
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time to progression of extraskeletal disease will be
presented, with corresponding 95% CIs for each arm
Clinical benefit endpoints
 Descriptive and graphical summaries will be
presented for each of the European Organisation for
Research and Treatment of Cancer Quality of Life
Group Bone Metastases Module (EORTC QLQ-
BM-22) and Brief Pain Inventory (BPI) question-
naires at each time point by arm. The EORTC
QLQ-BM-22 and BPI will be summarised by each
domain.
Study organisation and administration
The CARBON study is funded by Bayer Healthcare, sup-
ported by Yorkshire Cancer Research (YCR) through the
YCR Centre for Early Phase Clinical Trials, and is spon-
sored by the University of Leeds. Additional support is
also provided by the National Institute for Health Re-
search (NIHR) through the use of the Clinical Research
Network (CRN). Trial supervision will be established ac-
cording to the principles of Good Clinical Practice and
in line with the relevant Research Governance Frame-
work within the UK and through adherence with CTRU
standard operating procedures. A Standard Protocol
Items: Recommendations for Interventional Trials
(SPIRIT) Checklist has been prepared for this manu-
script (Additional file 1).
The trial is registered (ISRCTN92755158 and EudraCT
number 2015–003979-29).
Discussion
CARBON is an important and timely study as, despite
improved outcomes following breast cancer, 70% of par-
ticipants with advanced disease will develop skeletal The
median survival time after the development of bone me-
tastases is approximately 2–3 years despite the current
treatment options available.
As detailed above, the use of radium-223 as a thera-
peutic strategy for bone metastases is appealing due to
the supportive pre-clinical and clinical evidence of activ-
ity in prostate cancer. The development of radium-223
enables the opportunity to evaluate the toxicity and
tolerability of combining systemic therapy with a bone-
targeted agent.
The results of this phase IB/IIA study will help in-
form the design of subsequent phase II and -III stud-
ies that will facilitate the translation of this
combination into potential benefit for this participant
population.
Additional file
Additional file 1: Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) 2013 Checklist: recommended items to
address in a clinical trial protocol and related documents. (DOC 122 kb)
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